Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484704 | 0.86 | HSP90AA1 (0.56) | HSP90AA1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL485058 | 0.84 | HSP90AA1 (0.62) | HSP90AA1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2331325 | 0.83 | HSP90AA1 (0.50) | HSP90AA1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL484983 | 0.83 | HSP90AA1 (0.66) | HSP90AA1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3956227 | 0.83 | ESR1 (0.65) | HSP90AA1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL3081015 | 0.83 | HSP90AA1 (1.00) | HSP90AA1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL224762 | 0.82 | NPC1 (0.88) | HSP90AA1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1146960 | 0.81 | HSP90AA1 (0.74) | HSP90AA1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL4779632 | 0.81 | SMN1; SMN2 (0.62) | HSP90AA1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL5266853 | 0.81 | LMNA (0.63) | HSP90AA1NPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314132-B2 | 5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of Hsp90 chaperone and the intermediates for production thereof | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2012-11-20 | — | — | US | claimed |
| EP-2268626-B1 | 5-ARYL-4-(5-SUBSTITUTED 2,4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLES AS INHIBITORS OF HSP90 CHAPERONE AND THE INTERMEDIATES FOR PRODUCTION THEREOF | BIOTECHNOLOGIJOS INST (LT) | 2012-02-01 | — | — | EP | claimed |
| US-20110046387-A1 | 5-ARYL-4-(5-SUBSTITUTED 2,4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLES AS INHIBITORS OF HSP90 CHAPERONE AND THE INTERMEDIATES FOR PRODUCTION THEREOF | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2011-02-24 | — | — | US | claimed |
| EP-2268626-A1 | 5-ARYL-4-(5-SUBSTITUTED 2,4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLES AS INHIBITORS OF HSP90 CHAPERONE AND THE INTERMEDIATES FOR PRODUCTION THEREOF | Biotechnologijos Institutas (LT) | 2011-01-05 | — | — | EP | claimed |
| WO-2009134110-A1 | 5-ARYL-4-(5-SUBSTITUTED 2,4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLES AS INHIBITORS OF HSP90 CHAPERONE AND THE INTERMEDIATES FOR PRODUCTION THEREOF | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2009-11-05 | — | — | WO | claimed |
| US-8314132-B2 | 5-aryl-4-(5-substituted 2,4-dihydroxyphenyl)-1,2,3-thiadiazoles as inhibitors of Hsp90 chaperone and the intermediates for production thereof | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2012-11-20 | — | — | US | disclosed |
| EP-2268626-B1 | 5-ARYL-4-(5-SUBSTITUTED 2,4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLES AS INHIBITORS OF HSP90 CHAPERONE AND THE INTERMEDIATES FOR PRODUCTION THEREOF | BIOTECHNOLOGIJOS INST (LT) | 2012-02-01 | — | — | EP | disclosed |
| US-20110046387-A1 | 5-ARYL-4-(5-SUBSTITUTED 2,4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLES AS INHIBITORS OF HSP90 CHAPERONE AND THE INTERMEDIATES FOR PRODUCTION THEREOF | BIOTECHNOLOGIJOS INSTITUTAS (LT) | 2011-02-24 | — | — | US | disclosed |
| EP-2268626-A1 | 5-ARYL-4-(5-SUBSTITUTED 2,4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLES AS INHIBITORS OF HSP90 CHAPERONE AND THE INTERMEDIATES FOR PRODUCTION THEREOF | Biotechnologijos Institutas (LT) | 2011-01-05 | — | — | EP | disclosed |
| US-7632855-B2 | Pyrazole compounds as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-12-15 | — | — | US | disclosed |
| US-7632855-B2 | Pyrazole compounds as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-12-15 | — | — | US | disclosed |
| US-7632855-B2 | Pyrazole compounds as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-12-15 | — | — | US | disclosed |
| US-20070072855-A1 | 5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-methoxy-phenyl)-2H-pyrazole-3-carboxylic acid, for example; for treatment of diseases which are mediated by excessive or inappropriate HSP90 activity, such as cancers | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| US-20070072855-A1 | 5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-methoxy-phenyl)-2H-pyrazole-3-carboxylic acid, for example; for treatment of diseases which are mediated by excessive or inappropriate HSP90 activity, such as cancers | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-03-29 | — | — | US | disclosed |
| EP-1620090-A1 | PYRAZOLE COMPOUNDS AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | Vernalis (Cambridge) Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| WO-2004096212-A9 | PYRAZOLE COMPOUNDS AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS CAMBRIDGE LTD (GB) | 2005-03-31 | — | — | WO | disclosed |
| WO-2004096212-A1 | PYRAZOLE COMPOUNDS AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1456180-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | Vernalis (Oxford) Ltd (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003055860-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046387-A1 | 5-ARYL-4-(5-SUBSTITUTED 2,4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLES AS INHIBITORS OF HSP90 CHAPERONE AND THE INTERMEDIATES FOR PRODUCTION THEREOF | HSP90AB1, HSP90AB2P, HSP90AA1 | HSP90AA1 3/4885NPC1 1660/4885RAB9A 2696/4885 |
| US-20070072855-A1 | 5-(5-Chloro-2,4-dihydroxy-phenyl)-4-(4-methoxy-phenyl)-2H-pyrazole-3-carboxylic acid, for example; for treatment of diseases which are mediated by excessive or inappropriate HSP90 activity, such as cancers | HSP90AB1, HSP90AA1, NR5A2 | HSP90AA1 2/4885NPC1 2125/4885RAB9A 2828/4885 |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885NPC1 2190/4885RAB9A 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.